Monoclonal antibody therapies targeting the interaction between Programmed cell death protein 1 (PD-1) and its ligands, Programmed death- ligand 1 (PD-L1) and Programmed death- ligand 2 (PD-L2), have shown remarkable efficacy in treating and curing cancer [8,9]. This evidence concerns the gene PDCD1LG2 and cancer.